Related Experiment Video
Updated: Apr 11, 2026

Creating Virtual-hand and Virtual-face Illusions to Investigate Self-representation
Published on: March 1, 2017
Two Faces of SIVA
Lois Resnick-Silverman1, James J Manfredi2
1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract:
In non-small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options.
Insights
In non-small cell lung cancer, the gene SIVA promotes tumor growth by activating mTOR signaling. Inhibiting SIVA in mice stopped tumor development, suggesting SIVA as a potential therapeutic target for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Non-small cell lung cancer (NSCLC) with KRAS mutations presents limited therapeutic options.
- The p53 tumor suppressor pathway plays a critical role in apoptosis and cancer progression.
- SIVA is a known p53 target gene involved in regulating apoptosis.
Purpose of the Study:
- To investigate the role of SIVA in KRAS-mutated NSCLC.
- To determine the mechanism by which SIVA promotes tumorigenesis.
- To evaluate SIVA as a potential therapeutic target for NSCLC.
Main Methods:
- Analysis of SIVA expression in NSCLC cell lines with mutated KRAS.
- Investigating the p53-independent regulation of SIVA.
- Studying the impact of SIVA on mTOR signaling pathways.
- Utilizing conditional knockout mice to assess tumor development after SIVA ablation.
Main Results:
- SIVA is overexpressed in KRAS-mutated NSCLC cells independently of p53 status.
- SIVA overexpression stimulates tumor growth by activating mTOR signaling.
- Ablation of SIVA in mice significantly inhibits tumor development.
- These findings highlight SIVA's critical role in NSCLC tumorigenesis.
Conclusions:
- SIVA acts as an oncogene in KRAS-mutated NSCLC by promoting tumorigenesis via mTOR signaling.
- SIVA represents a promising novel therapeutic target for NSCLC, a cancer with unmet clinical needs.
- Targeting SIVA may offer a new strategy for treating patients with this challenging disease.
More Related Videos
08:02Rendering SiO2/Si Surfaces Omniphobic by Carving Gas-Entrapping Microtextures Comprising Reentrant and Doubly Reentrant Cavities or Pillars
Published on: February 11, 2020
08:15Reverse Dissection and DiceCT Reveal Otherwise Hidden Data in the Evolution of the Primate Face
Published on: January 7, 2019
Related Concept Videos
Understanding the Self
Sutures of the Skull
Sutures are immobile joints between adjacent bones of the skull. The narrow gap between the bones is filled with dense, fibrous connective tissue that unites the bones. The long sutures located between the skull bones are not straight but instead follow irregular, tightly twisting paths. These twisting lines tightly...
Symmetry
Personal Identity
Parallel-axis Theorem
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...